Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
385 participants
INTERVENTIONAL
2019-03-01
2026-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics of NAFLD Among Type 2 Diabetes Patients
NCT04999124
Screening for NAFLD in Flanders
NCT04647409
Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients
NCT04462081
NAFLD Among Patients With Type 2 Diabetes and CKD
NCT03826381
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
NCT06396871
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FibroScan
FibroScan
Performance of a FibroScan measurement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FibroScan
Performance of a FibroScan measurement.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having type 2 diabetes mellitus (T2DM)
* Written informed consent obtained
Exclusion Criteria
* Exclusion of other causes of liver disease and secondary causes of steatosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ziekenhuis Oost-Limburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathieu Struyve, MD
Role: PRINCIPAL_INVESTIGATOR
Ziekenhuis Oost-Limburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTU2019009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.